Iovance Biotherapeutics Inc Stock News

Iovance Biotherapeutics' Q3 earnings outperformed expectations, with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Amtagvi, Iovance's lead drug, shows strong commercial potential with 2025 revenue guidance of $450-$475m and significant opportunities in melanoma and other cancers including NSCLC. Despite high cash burn and competition, Iovance's gro...

Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript

Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in  Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of  Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accele...

SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024.

With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.

The biotech is making important breakthroughs, but is that enough?

Iovance Biotherapeutics' Amtagvi has gained rapid market traction post-FDA approval, with strong Q3 performance and promising revenue projections for 2024 and beyond. The company's growth prospects are bolstered by potential regulatory approvals in international markets and ongoing trials in other cancer types, including NSCLC. Despite the positive outlook, risks include market penetration chal...

Iovance Biotherapeutics is laying the groundwork to start realizing lots of revenue. It also has a lot of work in progress to increase the number of patients it can help.